Library
PubMed
research article
Professional

Stepwise Targeted Screening for Familial Hypercholesterolemia in a Resource-Limited Setting: A Scalable Model Linking Premature Coronary Artery Disease and Community Screening in Vietnam.

Source: PubMed, NCBI / U.S. National Library of Medicine

Global heartTruong Thanh-Huong, Do Doan-Loi, Vu Minh-Phuong, et al.Published 1/1/2026Last synced 5/26/2026Status: syncedPMID: 42180794DOI: 10.5334/gh.1557

Familial hypercholesterolemia (FH) is a common autosomal dominant disorder associated with a substantially increased risk of atherosclerotic cardiovascular disease. In low- and middle-income countries (LMICs), universal FH screening is often impractical, highlighting the need for targeted screening strategies embedded within existing health systems. To evaluate the detection yield and real-world implementation feasibility of a stepwise targeted FH screening strategy in a resource-limited setting. This multi-component implementation study included retrospective and prospective hospital-based screening of patients with premature coronary artery disease (CAD), followed by a geographically targeted community-based screening program linked to a genetically confirmed FH index case in Vietnam. FH was assessed using the Dutch Lipid Clinic Network criteria, with LDL-C thresholds applied for community-level screening. Among patients with premature CAD, phenotypic FH was identified in 2.5% and 8.3% of the retrospective and prospective cohorts, respectively. The higher detection rate in the prospective cohort may reflect more systematic phenotyping. In the community screening, 59.1% of eligible individuals participated, and 10.6% had LDL-C levels ≥ 4.9 mmol/L. A stepwise targeted FH screening strategy-initiated in clinical populations and extended via geographically targeted community screening-demonstrates feasibility and potential scalability in resource-limited settings and may

Abstract

Familial hypercholesterolemia (FH) is a common autosomal dominant disorder associated with a substantially increased risk of atherosclerotic cardiovascular disease. In low- and middle-income countries (LMICs), universal FH screening is often impractical, highlighting the need for targeted screening strategies embedded within existing health systems. To evaluate the detection yield and real-world implementation feasibility of a stepwise targeted FH screening strategy in a resource-limited setting. This multi-component implementation study included retrospective and prospective hospital-based screening of patients with premature coronary artery disease (CAD), followed by a geographically targeted community-based screening program linked to a genetically confirmed FH index case in Vietnam. FH was assessed using the Dutch Lipid Clinic Network criteria, with LDL-C thresholds applied for community-level screening. Among patients with premature CAD, phenotypic FH was identified in 2.5% and 8.3% of the retrospective and prospective cohorts, respectively. The higher detection rate in the prospective cohort may reflect more systematic phenotyping. In the community screening, 59.1% of eligible individuals participated, and 10.6% had LDL-C levels ≥ 4.9 mmol/L. A stepwise targeted FH screening strategy-initiated in clinical populations and extended via geographically targeted community screening-demonstrates feasibility and potential scalability in resource-limited settings and may provide a pragmatic framework for integration into national NCD programs in LMICs. - Targeted screening strategies may enhance the detection of FH in resource-limited settings where universal screening is not feasible.- Patients with premature coronary artery disease represent a high FH detection rate.- Geographically targeted community-based screening linked to FH index cases enables identification of individuals with markedly elevated LDL-C levels.- A stepwise approach combining hospital-based and community-based screening may provide a scalable model for FH detection in LMICs.

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.